330 related articles for article (PubMed ID: 34148467)
1. Genotyping
Jantararoungtong T; Tempark T; Koomdee N; Medhasi S; Sukasem C
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1049-1064. PubMed ID: 34148467
[No Abstract] [Full Text] [Related]
2. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children.
Manuyakorn W; Likkasittipan P; Wattanapokayakit S; Suvichapanich S; Inunchot W; Wichukchinda N; Khongkhatithuml C; Thampratankul L; Kamchaisatian W; Benjaponpitak S; Mahasirimongkol S
Epilepsy Res; 2020 May; 162():106321. PubMed ID: 32272329
[TBL] [Abstract][Full Text] [Related]
3. A recent update of pharmacogenomics in drug-induced severe skin reactions.
Wei CY; Ko TM; Shen CY; Chen YT
Drug Metab Pharmacokinet; 2012; 27(1):132-41. PubMed ID: 22041139
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Borroni RG
G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
[TBL] [Abstract][Full Text] [Related]
5. Genetic Association of Co-Trimoxazole-Induced Severe Cutaneous Adverse Reactions Is Phenotype-Specific: HLA Class I Genotypes and Haplotypes.
Sukasem C; Pratoomwun J; Satapornpong P; Klaewsongkram J; Rerkpattanapipat T; Rerknimitr P; Lertpichitkul P; Puangpetch A; Nakkam N; Konyoung P; Khunarkornsiri U; Disphanurat W; Srisuttiyakorn C; Pattanacheewapull O; Kanjanawart S; Kongpan T; Chumworathayi P; Saksit N; Bruminhent J; Tassaneeyakul W; Chantratita W; Pirmohamed M
Clin Pharmacol Ther; 2020 Nov; 108(5):1078-1089. PubMed ID: 32452529
[TBL] [Abstract][Full Text] [Related]
6. Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.
Sukasem C; Chaichan C; Nakkrut T; Satapornpong P; Jaruthamsophon K; Jantararoungtong T; Koomdee N; Sririttha S; Medhasi S; Oo-Puthinan S; Rerkpattanapipat T; Klaewsongkram J; Rerknimitr P; Tuchinda P; Chularojanamontri L; Tovanabutra N; Puangpetch A; Aekplakorn W
J Immunol Res; 2018; 2018():2780272. PubMed ID: 29546073
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of cutaneous adverse drug reactions.
Aihara M
J Dermatol; 2011 Mar; 38(3):246-54. PubMed ID: 21342226
[TBL] [Abstract][Full Text] [Related]
8. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.
Chang CC; Ng CC; Too CL; Choon SE; Lee CK; Chung WH; Hussein SH; Lim KS; Murad S
Pharmacogenomics J; 2017 Mar; 17(2):170-173. PubMed ID: 26927288
[TBL] [Abstract][Full Text] [Related]
9. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
10. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
11. Association between
Wattanachai P; Amornpinyo W; Konyoung P; Purimart D; Khunarkornsiri U; Pattanacheewapull O; Tassaneeyakul W; Nakkam N
Front Pharmacol; 2023; 14():1248386. PubMed ID: 37795024
[No Abstract] [Full Text] [Related]
12. Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions.
Pan RY; Dao RL; Hung SI; Chung WH
Clin Pharmacol Ther; 2017 Jul; 102(1):86-97. PubMed ID: 28295240
[TBL] [Abstract][Full Text] [Related]
13. Role of dermatology in pharmacogenomics: drug-induced skin injury.
Borroni RG
Pharmacogenomics; 2015; 16(4):401-12. PubMed ID: 25823788
[TBL] [Abstract][Full Text] [Related]
14. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.
Cheng CY; Su SC; Chen CH; Chen WL; Deng ST; Chung WH
J Immunol Res; 2014; 2014():565320. PubMed ID: 24901010
[TBL] [Abstract][Full Text] [Related]
15. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Review of
Kloypan C; Koomdee N; Satapornpong P; Tempark T; Biswas M; Sukasem C
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832859
[TBL] [Abstract][Full Text] [Related]
17. Severe cutaneous adverse reactions.
Hung SI; Mockenhaupt M; Blumenthal KG; Abe R; Ueta M; Ingen-Housz-Oro S; Phillips EJ; Chung WH
Nat Rev Dis Primers; 2024 Apr; 10(1):30. PubMed ID: 38664435
[TBL] [Abstract][Full Text] [Related]
18. Current understanding of genetic associations with delayed hypersensitivity reactions induced by antibiotics and anti-osteoporotic drugs.
Wung CH; Wang CW; Lai KC; Chen CB; Chen WT; Hung SI; Chung WH;
Front Pharmacol; 2023; 14():1183491. PubMed ID: 37180708
[TBL] [Abstract][Full Text] [Related]
19. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
20. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
